Actinic keratosis: where do we stand and where is the future going to take us? / Philipp Cramer, Eggert Stockfleth
ABSTRACT Introduction : Actinic keratosis (AK) is a chronic disease which is mainly located across areas of sun-exposed skin. Clinical and subclinical lesions coexist across a large area resulting in a field cancerization. As these lesions have the potential to transform into invasive squamous cell carcinoma (iSCC), treatment is crucial. With global prevalence increasing, AK is expected to be the most common in situ carcinoma of the skin. Areas covered : In this article, we cover the established algorithm of treating AK and give an insight into the drugs under development. There are six compounds under development covering different treatment angles, from Sinecatechin a Polyphenon E which targets the link between HPV infection and development of AK, over Tirbanibulin which targets the SRC proto-oncogene and fast proliferating cells, to Tuvatexib a small-molecule dual VDAC/HK2 modulator that has shown that it can compete with the established therapies. Expert opinion : These new treatment options are moving us further toward a more individually tailored treatment for each patient considering his abilities, the size and location of his lesions but also the genetic bases as well as individual risk of transforming into a iSCC and possibly other factors contributing to each patients individual AK lesions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 25(2020), 1, Seite 49-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cramer, Philipp [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (10 p) |
|---|
| doi: |
10.1080/14728214.2020.1730810 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011201819 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011201819 | ||
| 003 | DE-627 | ||
| 005 | 20230720210245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2020.1730810 |2 doi | |
| 035 | |a (DE-627)KFL011201819 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/14728214.2020.1730810 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Cramer, Philipp |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Actinic keratosis: where do we stand and where is the future going to take us? |c Philipp Cramer, Eggert Stockfleth |
| 264 | 1 | |c 2020 | |
| 300 | |a 1 Online-Ressource (10 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction : Actinic keratosis (AK) is a chronic disease which is mainly located across areas of sun-exposed skin. Clinical and subclinical lesions coexist across a large area resulting in a field cancerization. As these lesions have the potential to transform into invasive squamous cell carcinoma (iSCC), treatment is crucial. With global prevalence increasing, AK is expected to be the most common in situ carcinoma of the skin. Areas covered : In this article, we cover the established algorithm of treating AK and give an insight into the drugs under development. There are six compounds under development covering different treatment angles, from Sinecatechin a Polyphenon E which targets the link between HPV infection and development of AK, over Tirbanibulin which targets the SRC proto-oncogene and fast proliferating cells, to Tuvatexib a small-molecule dual VDAC/HK2 modulator that has shown that it can compete with the established therapies. Expert opinion : These new treatment options are moving us further toward a more individually tailored treatment for each patient considering his abilities, the size and location of his lesions but also the genetic bases as well as individual risk of transforming into a iSCC and possibly other factors contributing to each patients individual AK lesions | ||
| 653 | |a Actinic keratosis | ||
| 653 | |a squamous cell carcinoma | ||
| 653 | |a cryotherapy | ||
| 653 | |a 5-fuorouracil | ||
| 653 | |a Imiquimod | ||
| 653 | |a Ingenol Mebutate | ||
| 653 | |a Diclofenac | ||
| 653 | |a photodynamic therapy | ||
| 653 | |a polyphenon E | ||
| 653 | |a Paclitaxel | ||
| 653 | |a tubulin beta class I | ||
| 653 | |a potassium dobesilate | ||
| 653 | |a Tirbanibulin | ||
| 653 | |a SRC proto-oncogene | ||
| 653 | |a Furosemide and Digoxin | ||
| 653 | |a Tuvatexib | ||
| 653 | |a VDAC/HK2 modulator | ||
| 700 | 1 | |a Stockfleth, Eggert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 2001 |g 25(2020), 1, Seite 49-58 |h Online-Ressource |w (DE-627)KFL000006033 |w (DE-600)2030079-7 |w (DE-576)302969306 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g number:1 |g pages:49-58 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/14728214.2020.1730810 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2020 |e 1 |h 49-58 | ||